Study of Simmitinib plus SG001 for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two experimental drugs, Simmitinib and SG001, in people with advanced solid tumors that have stopped responding to standard treatments. It aims to find out if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your cancer must be advanced and cannot be removed by surgery, and you have either not responded to or cannot tolerate standard treatments.
- You need to have at least one tumor that can be measured on scans.
- You must be in good overall health (ECOG score 0 or 1).
- Your blood counts, liver, kidney, and heart function must be within certain limits.
- If you are in the expansion phase, you must agree to provide a tumor sample for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two experimental drugs (SY-5933 and CT-707) for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the combination is safe and effective.
This Phase 1/2 trial tests SGN1 in people with advanced solid tumors whose cancer has grown despite standard treatments, or who could not tolerate them. The study aims to find a safe dose and see whether the drug can work in certain cancer types.
This Phase 1 trial tests a new medicine (HG381) in people with advanced solid tumors to see how safe it is and how it works in the body. It may help if standard treatments have already stopped working or aren’t possible for you.
This is an early-stage trial testing a new drug called SIM0613 for advanced cancers that have spread or grown despite other treatments. The drug is designed to target cancer cells using a special delivery system.
This trial tests an investigational new drug, SIM0609, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see early signs that it might help slow or shrink tumors.
This trial tests a new drug (SIM0686) in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how it affects tumors that have a specific protein called FGFR2b on their surface.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.